16:19 , Jun 15, 2018 |  BC Week In Review  |  Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on June 11, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also...
22:51 , Jun 11, 2018 |  BC Extra  |  Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on Monday, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also divested...
23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral sclerosis...
08:00 , Dec 15, 2014 |  BioCentury  |  Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics. Momenta...
07:00 , Aug 18, 2014 |  BioCentury  |  Finance

Flagship's fashion

Venture investment models come and go out of fashion, but Flagship Ventures has stuck with its thesis that novel, early stage platform companies with significant disruptive potential are the way to go. And rather than...
07:00 , Mar 11, 2013 |  BioCentury  |  Emerging Company Profile

FPRT Bio: Neutralizing neuroinflammation

FPRT Bio Inc. is developing a protein therapeutic that could halt neurodegeneration in amyotrophic lateral sclerosis and Parkinson's disease by blocking inflammatory signaling that causes neuronal cell death. FPRT's sole asset is XPro1595, a subcutaneously administered...
07:00 , Oct 29, 2012 |  BioCentury  |  Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
07:00 , Aug 2, 2010 |  BioCentury  |  Regulation

Equivalence test case

Equivalence test case By Susan Schaeffer Managing Editor While FDA's response to a Citizen's Petition lodged by sanofi-aventis Group specifically addresses the requirements for demonstrating the equivalence of enoxaparin products, it sheds light on the technical rigor...
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

Accuri Cytometers Inc., IncellDx Inc. sales and marketing update

Accuri will supply IncellDx with its Accuri C6 Flow Cytometer for use in combination with IncellDx's HPV OncoTect. IncellDx will market Accuri's cytometers when used with its HPV OncoTect test. The HPV OncoTect E6, E7...